Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New drugs for old.

Alan Winston1, Justin Stebbing

  • 1National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Sydney, Australia.

Journal of HIV Therapy
|June 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refining inflammatory profiles linked to cardiometabolic outcomes in people with HIV using recursive feature addition modelling.

Clinical and translational medicine·2026
Same author

The role of premorbid cognitive performance in the neuropsychological assessment of people with HIV in South Africa.

PloS one·2026
Same author

Consideration of brain health in ART interruption studies.

The lancet. HIV·2026
Same author

Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ART.

Current HIV/AIDS reports·2026
Same author

Refining biomarker-based clustering of cardiovascular inflammatory phenotypes in HIV using Recursive Feature Addition: A comparative evaluation approach.

PLoS computational biology·2026
Same author

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART.

HIV medicine·2026
Same journal

Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.

Journal of HIV therapy·2010
Same journal

A review of the use of activation markers in Africa.

Journal of HIV therapy·2010
Same journal

Lymphocyte activation in HIV-1 infection: time for quality control.

Journal of HIV therapy·2010
Same journal

HIV immunology: what lessons can we learn from recent vaccine trials?

Journal of HIV therapy·2010
Same journal

SILCAAT and ESPRIT: taking stock.

Journal of HIV therapy·2010
Same journal

HIV, atherosclerosis and inflammation: implications for treatment.

Journal of HIV therapy·2010
See all related articles

Highly active antiretroviral therapy (HAART) has led to drug-resistant HIV. New treatments must target both wild-type and mutant viruses, offering simplified regimens and favorable toxicity profiles for long-term HIV management.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Highly active antiretroviral therapy (HAART) has driven the evolution of HIV drug resistance mutations.
  • Emerging cases of highly resistant HIV infections are linked to rapid progression to Acquired Immunodeficiency Syndrome (AIDS).

Purpose of the Study:

  • To outline the essential features of novel drugs for treating HIV infection.
  • To address the need for agents effective against both wild-type and drug-resistant HIV strains.
  • To emphasize the importance of simplified dosing and favorable toxicity profiles for long-term patient adherence and management.

Main Methods:

  • Review of current challenges in HIV treatment due to drug resistance.
  • Analysis of requirements for new antiretroviral agents.

Related Experiment Videos

  • Consideration of patient adherence and long-term management strategies.

    • Main Results:

    • Development of resistance-associated mutations is a consequence of HAART.
    • New HIV drug candidates must exhibit potent activity against both susceptible and resistant viral strains.
    • Simplified dosing regimens and improved toxicity profiles are crucial for patient adherence in chronic HIV management.

    Conclusions:

    • Novel antiretroviral drugs are needed to combat resistant HIV strains.
    • Future HIV therapies should prioritize broad-spectrum activity and patient-centric features like simplified regimens and reduced toxicity.
    • Strategic replacement of older therapies with newer agents that circumvent cross-resistance offers a promising approach to retroviral targeting.